This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Reilly JT . Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997; 11: 2133.
Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M . Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114: 78–83.
Canepa L, Ballerini F, Varaldo R, Quintino S, Reni L, Clavio M et al. Thalidomide in angiogenic and secondary myelofibrosis. Br J Haematol 2001; 115: 313–315.
Pozzato G, Zorat F, Nascimben F, Comar C, Kikic F, Festini G . Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia. Haematologica 2001; 86: 772–773.
Elliott MA, Mesa RA, Li C-Y, Hook CC, Ansell MA, Levitt RM et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 117: 288–296.
Piccaluga PP, Visani G, Pileri SA, Ascani S, Grafone T, Isidori A et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 2002; 16: 1609–1614.
Rodriguez JN, Martino ML, Dieguez JC, Prados D . RHuEPO for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 1998; 83: 616–621.
Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematology 1990; 75: 4–9.
Acknowledgements
This work was supported in part by AIL Pesaro ONLUS.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Visani, G., Mele, A., Malagola, M. et al. Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents. Leukemia 17, 1669–1670 (2003). https://doi.org/10.1038/sj.leu.2403017
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403017